Targeted Oncology· @TargetedOnc · X·· 22 小时前评分70
正文 · 机器翻译
从乳腺癌研究开始，#ESMO26。KEYNOTE-B49 探讨 pembrolizumab + 化疗能否改善 HR+/HER2− 晚期疾病的结局。我尤其关注 PD-L1 指标选择、OS、毒性 & 在 CDK4/6 抑制剂之后的定位。摘要要点如下
89 浏览 · 1 赞 · 0 转发 · 0 回复
会议摘要
LBA51按 Proffered paper 2: Breast cancer, early and advanced stage 对上
Results from KEYNOTE-B49: A phase 3, randomized, double-blind study of pembrolizumab (pembro) vs placebo (pbo) plus chemotherapy (CT) in participants (pts) with HR+/HER2− advanced breast cancer (ABC)
https://esmocongress.esmo.org来源：Targeted Oncology · x.com